OBI is featured in the Bioconjugate Insights on Bispecific and Dual-Payload ADC Design Strategies
Focusing on Approaches to Address Tumor Heterogeneity and Drug Resistance

OBI Pharma (4174.TWO) announced that its Chief Scientific Officer, Dr. Ya-Chi Chen, was recently featured in an interview with the prestigious international media platform Bioconjugate Insights, where she shared the company’s innovative strategies for next-generation antibody–drug conjugates (ADCs). In the interview, Dr. Chen provided insights into how rational design approaches can address key clinical challenges, including tumor heterogeneity and drug resistance.

HOMEWhat’s NewNewsOBI is featured in the Bioconjugate Insights on Bispecific and Dual-Payload ADC Design Strategies Focusing on Approaches to Address Tumor Heterogeneity and Drug Resistance

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2026.Apr.15

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies